Clovis Oncology (NASDAQ:CLVS) Insider Buys $279,500.00 in Stock

Share on StockTwits

Clovis Oncology (NASDAQ:CLVS) insider Patrick J. Mahaffy purchased 50,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $5.59 per share, for a total transaction of $279,500.00. Following the completion of the purchase, the insider now owns 919,187 shares of the company’s stock, valued at $5,138,255.33. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

CLVS opened at $6.06 on Thursday. The business’s fifty day moving average is $10.07 and its two-hundred day moving average is $18.39. The company has a current ratio of 3.57, a quick ratio of 3.32 and a debt-to-equity ratio of 8.04. Clovis Oncology has a one year low of $4.98 and a one year high of $37.27.

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($2.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.70) by ($0.57). The firm had revenue of $32.98 million for the quarter, compared to analysts’ expectations of $34.92 million. Clovis Oncology had a negative return on equity of 372.68% and a negative net margin of 332.18%. The firm’s revenue for the quarter was up 38.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.94) earnings per share. Analysts forecast that Clovis Oncology will post -7.44 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP purchased a new position in shares of Clovis Oncology in the fourth quarter worth approximately $5,641,000. Legal & General Group Plc boosted its holdings in shares of Clovis Oncology by 29.9% in the fourth quarter. Legal & General Group Plc now owns 20,457 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 4,711 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Clovis Oncology by 258.4% in the fourth quarter. Millennium Management LLC now owns 29,109 shares of the biopharmaceutical company’s stock worth $523,000 after buying an additional 20,988 shares during the last quarter. Norges Bank purchased a new position in shares of Clovis Oncology in the fourth quarter worth approximately $8,351,000. Finally, Virtu Financial LLC bought a new stake in Clovis Oncology during the 1st quarter worth approximately $215,000. Institutional investors own 92.13% of the company’s stock.

A number of research firms recently weighed in on CLVS. G.Research restated a “buy” rating on shares of Clovis Oncology in a research note on Friday, August 2nd. Guggenheim downgraded Clovis Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Royal Bank of Canada set a $26.00 price target on Clovis Oncology and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, HC Wainwright restated a “buy” rating on shares of Clovis Oncology in a research note on Wednesday, July 3rd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $25.09.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

See Also: Can individual investors take part in an IPO?

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

VANGUARD SCOTTS/VANGUARD RUSSELL 20  Shares Acquired by Wells Fargo & Company MN
VANGUARD SCOTTS/VANGUARD RUSSELL 20 Shares Acquired by Wells Fargo & Company MN
$1.41 EPS Expected for Burlington Stores Inc  This Quarter
$1.41 EPS Expected for Burlington Stores Inc This Quarter
$1.79 Billion in Sales Expected for Burlington Stores Inc  This Quarter
$1.79 Billion in Sales Expected for Burlington Stores Inc This Quarter
Public Employees Retirement System of Ohio Has $2.94 Million Holdings in Wyndham Destinations
Public Employees Retirement System of Ohio Has $2.94 Million Holdings in Wyndham Destinations
Public Employees Retirement System of Ohio Buys Shares of 34,182 Guardant Health Inc
Public Employees Retirement System of Ohio Buys Shares of 34,182 Guardant Health Inc
Public Employees Retirement System of Ohio Grows Position in Empire State Realty Trust Inc
Public Employees Retirement System of Ohio Grows Position in Empire State Realty Trust Inc


© 2006-2019 Ticker Report